Literature DB >> 2583854

Effect of tetrandrine on immunological responses and cardiac transplant rejection in mice.

S Y Li1, B S Teh, W K Seow, L H Ling, Y H Thong.   

Abstract

Mice treated with the plant alkaloid tetrandrine have a reduced capacity to mount delayed-type hypersensitivity (DTH) responses. This suppressive effect on DTH was more pronounced when treatment was begun 2 days prior to immunization with sheep erythrocytes. Similar dosage regimens significantly delayed the rejection of cardiac transplants. By contrast, there was significant enhancement of antibody production. These immunomodulatory properties of tetrandrine may account for some of its potential in the treatment of chronic inflammatory diseases, where immunological mechanisms are known to play a major role in pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583854     DOI: 10.1159/000235019

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  5 in total

1.  Anti-inflammatory activity of the isoquinoline alkaloid, tetrandrine, against established adjuvant arthritis in rats.

Authors:  M W Whitehouse; D P Fairlie; Y H Thong
Journal:  Agents Actions       Date:  1994-10

2.  Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor.

Authors:  C W Wong; W K Seow; J W O'Callaghan; Y H Thong
Journal:  Agents Actions       Date:  1992-05

Review 3.  The potential of tetrandrine as a protective agent for ischemic stroke.

Authors:  Yun Chen; Ya-Hui Tsai; Sheng-Hong Tseng
Journal:  Molecules       Date:  2011-09-16       Impact factor: 4.411

4.  Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha.

Authors:  W K Seow; K Nakamura; Y Sugimura; Y Sugimoto; Y Yamada; D P Fairlie; Y H Thong
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

Review 5.  Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.

Authors:  Paula M Heister; Robin N Poston
Journal:  Pharmacol Res Perspect       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.